Year |
Citation |
Score |
2016 |
John SF, Aniemeke E, Ha NP, Chong CR, Gu P, Zhou J, Zhang Y, Graviss EA, Liu JO, Olaleye OA. Characterization of 2-hydroxy-1-naphthaldehyde isonicotinoyl hydrazone as a novel inhibitor of methionine aminopeptidases from Mycobacterium tuberculosis. Tuberculosis (Edinburgh, Scotland). PMID 27856197 DOI: 10.1016/J.Tube.2016.09.025 |
0.707 |
|
2016 |
Chong CR, Bahcall M, Capelletti M, Kosaka T, Ercan D, Sim T, Sholl LM, Nishino M, Johnson BE, Gray NS, Janne PA. Identification of existing drugs that effectively target NTRK1- and ROS1-rearrangements in lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27370605 DOI: 10.1158/1078-0432.Ccr-15-1601 |
0.391 |
|
2015 |
Lee HG, Kim H, Kim EJ, Park PG, Dong SM, Choi TH, Kim H, Chong CR, Liu JO, Chen J, Ambinder RF, Hayward SD, Park JH, Lee JM. Targeted therapy for Epstein-Barr virus-associated gastric carcinoma using low-dose gemcitabine-induced lytic activation. Oncotarget. PMID 26427042 DOI: 10.18632/Oncotarget.5041 |
0.449 |
|
2015 |
Chong C, Ercan D, Bahcall M, Capelletti M, Gray N, Janne P. Abstract 3644: Identification of existing targeted agents that inhibit NTRK and ROS1 in lung cancer Cancer Research. 75: 3644-3644. DOI: 10.1158/1538-7445.Am2015-3644 |
0.408 |
|
2014 |
Mu XJ, Allen EV, Wagle N, Chong C, Butaney M, Farlow D, Getz G, Jänne PA, Garraway LA. Abstract 2371: Heterogeneity of resistance mechanisms in lung adenocarcinoma patients with acquired resistance to EGFR inhibitors Cancer Research. 74: 2371-2371. DOI: 10.1158/1538-7445.Am2014-2371 |
0.307 |
|
2013 |
Chong CR, Jänne PA. The quest to overcome resistance to EGFR-targeted therapies in cancer. Nature Medicine. 19: 1389-400. PMID 24202392 DOI: 10.1038/Nm.3388 |
0.32 |
|
2012 |
Bhat S, Shim JS, Zhang F, Chong CR, Liu JO. Substituted oxines inhibit endothelial cell proliferation and angiogenesis. Organic & Biomolecular Chemistry. 10: 2979-92. PMID 22391578 DOI: 10.1039/C2Ob06978D |
0.752 |
|
2011 |
Platz EA, Yegnasubramanian S, Liu JO, Chong CR, Shim JS, Kenfield SA, Stampfer MJ, Willett WC, Giovannucci E, Nelson WG. A novel two-stage, transdisciplinary study identifies digoxin as a possible drug for prostate cancer treatment. Cancer Discovery. 1: 68-77. PMID 22140654 DOI: 10.1158/2159-8274.Cd-10-0020 |
0.597 |
|
2011 |
Olaleye O, Raghunand TR, Bhat S, Chong C, Gu P, Zhou J, Zhang Y, Bishai WR, Liu JO. Characterization of clioquinol and analogues as novel inhibitors of methionine aminopeptidases from Mycobacterium tuberculosis. Tuberculosis (Edinburgh, Scotland). 91: S61-5. PMID 22115541 DOI: 10.1016/J.Tube.2011.10.012 |
0.748 |
|
2010 |
Shim JS, Matsui Y, Bhat S, Nacev BA, Xu J, Bhang HE, Dhara S, Han KC, Chong CR, Pomper MG, So A, Liu JO. Effect of nitroxoline on angiogenesis and growth of human bladder cancer. Journal of the National Cancer Institute. 102: 1855-73. PMID 21088277 DOI: 10.1093/Jnci/Djq457 |
0.73 |
|
2010 |
Kim J, Tang JY, Gong R, Kim J, Lee JJ, Clemons KV, Chong CR, Chang KS, Fereshteh M, Gardner D, Reya T, Liu JO, Epstein EH, Stevens DA, Beachy PA. Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth. Cancer Cell. 17: 388-99. PMID 20385363 DOI: 10.1016/J.Ccr.2010.02.027 |
0.448 |
|
2008 |
Ren YR, Pan F, Parvez S, Fleig A, Chong CR, Xu J, Dang Y, Zhang J, Jiang H, Penner R, Liu JO. Clofazimine inhibits human Kv1.3 potassium channel by perturbing calcium oscillation in T lymphocytes. Plos One. 3: e4009. PMID 19104661 DOI: 10.1371/Journal.Pone.0004009 |
0.657 |
|
2008 |
Downey AS, Chong CR, Graczyk TK, Sullivan DJ. Efficacy of pyrvinium pamoate against Cryptosporidium parvum infection in vitro and in a neonatal mouse model. Antimicrobial Agents and Chemotherapy. 52: 3106-12. PMID 18591280 DOI: 10.1128/Aac.00207-08 |
0.365 |
|
2007 |
Byrne ST, Gu P, Zhou J, Denkin SM, Chong C, Sullivan D, Liu JO, Zhang Y. Pyrrolidine dithiocarbamate and diethyldithiocarbamate are active against growing and nongrowing persister Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy. 51: 4495-7. PMID 17876006 DOI: 10.1128/Aac.00753-07 |
0.329 |
|
2007 |
Chong CR, Sullivan DJ. New uses for old drugs. Nature. 448: 645-6. PMID 17687303 DOI: 10.1038/448645A |
0.381 |
|
2007 |
McMahon MA, Jilek BL, Brennan TP, Shen L, Zhou Y, Wind-Rotolo M, Xing S, Bhat S, Hale B, Hegarty R, Chong CR, Liu JO, Siliciano RF, Thio CL. The HBV drug entecavir - effects on HIV-1 replication and resistance. The New England Journal of Medicine. 356: 2614-21. PMID 17582071 DOI: 10.1056/Nejmoa067710 |
0.66 |
|
2007 |
Chong CR, Xu J, Lu J, Bhat S, Sullivan DJ, Liu JO. Inhibition of angiogenesis by the antifungal drug itraconazole. Acs Chemical Biology. 2: 263-70. PMID 17432820 DOI: 10.1021/Cb600362D |
0.764 |
|
2006 |
Allen MD, DiPilato LM, Rahdar M, Ren YR, Chong C, Liu JO, Zhang J. Reading dynamic kinase activity in living cells for high-throughput screening. Acs Chemical Biology. 1: 371-6. PMID 17163774 DOI: 10.1021/Cb600202F |
0.726 |
|
2006 |
Chen X, Chong CR, Shi L, Yoshimoto T, Sullivan DJ, Liu JO. Inhibitors of Plasmodium falciparum methionine aminopeptidase 1b possess antimalarial activity. Proceedings of the National Academy of Sciences of the United States of America. 103: 14548-53. PMID 16983082 DOI: 10.1073/Pnas.0604101103 |
0.648 |
|
2006 |
Lu J, Chong CR, Hu X, Liu JO. Fumarranol, a rearranged fumagillin analogue that inhibits angiogenesis in vivo. Journal of Medicinal Chemistry. 49: 5645-8. PMID 16970390 DOI: 10.1021/Jm060559V |
0.674 |
|
2006 |
Chong CR, Chen X, Shi L, Liu JO, Sullivan DJ. A clinical drug library screen identifies astemizole as an antimalarial agent. Nature Chemical Biology. 2: 415-6. PMID 16816845 DOI: 10.1038/Nchembio806 |
0.638 |
|
2006 |
Chong CR, Qian DZ, Pan F, Wei Y, Pili R, Sullivan DJ, Liu JO. Identification of type 1 inosine monophosphate dehydrogenase as an antiangiogenic drug target. Journal of Medicinal Chemistry. 49: 2677-80. PMID 16640327 DOI: 10.1021/Jm051225T |
0.692 |
|
2003 |
Chong CR, Sullivan DJ. Inhibition of heme crystal growth by antimalarials and other compounds: Implications for drug discovery Biochemical Pharmacology. 66: 2201-2212. PMID 14609745 DOI: 10.1016/J.Bcp.2003.08.009 |
0.36 |
|
Show low-probability matches. |